Arecor Therapeutics PLC Arecor on Investor Meet Company Platform (4464J)
27 April 2022 - 4:01PM
UK Regulatory
TIDMAREC
RNS Number : 4464J
Arecor Therapeutics PLC
27 April 2022
Arecor Therapeutics plc
("Arecor" or the "Group")
Arecor to present on Investor Meet Company Platform
Cambridge, UK, 27 April 2022: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, today announces that Sarah Howell, Chief
Executive Officer and Susan Lowther, Chief Financial Officer will
be providing a live presentation relating to the Group's recently
announced Year End Results for the year ended 31 December 2021 via
the Investor Meet Company platform, on Thursday 5 May 2022 at
10:00am BST.
The presentation is open to all existing and potential
shareholders and will be followed by a Q&A session. Questions
can be submitted ahead of the event through the Investor Meet
Company dashboard until 9am BST on Wednesday 4 May, or at any time
during the live presentation.
To sign up to Investor Meet Company for free and to register for
Arecor's presentation, please visit:
https://www.investormeetcompany.com/arecor-therapeutics-plc/register-investor
. Investors who already follow Arecor on the Investor Meet Company
platform will automatically be invited to the event.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary formulation technology
platform, Arestat(TM) , we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat (TM) platform is supported by an extensive patent portfolio
.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUNAKRUSUSUAR
(END) Dow Jones Newswires
April 27, 2022 02:01 ET (06:01 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2023 to Apr 2024